SAN DIEGO, March 30, 2012 /PRNewswire/ -- Genalyte, Inc., a life sciences company developing and commercializing innovative next-generation multiplexing technology, today announced completion of an $11.8 million Series B financing. New investors Redmile Group and Claremont Creek Ventures and private investors from Genalyte's Series A round participated in the Series B financing. Genalyte intends to use the new funds primarily for commercialization of its Maverick™ platform and its highly multiplexed panels for autoimmune and immunoassay applications.
Genalyte has pioneered an entirely new approach to immunodetection using silicon chip manufacturing methods. The Maverick platform uses a technology called silicon photonics to directly measure protein binding between antibodies and antigens or hybridization of nucleic acids. This technology eliminates the need for complex processing associated with current multiplexed testing, while leveraging the manufacturing advantages of silicon chips. Genalyte is preparing to launch the Maverick platform this summer, initially addressing the autoimmunity research and testing markets.
"By applying advances in silicon photonics to the life sciences, we have been able to develop a completely new approach to biological detection that provides major advantages to researchers and, eventually, to clinicians," commented Genalyte CEO and founder Cary Gunn. "Our initial funding enabled us to fully develop and refine the silicon photonics biosensor consumables that are the heart of the Maverick system, along with the instrument itself and our initial multiplexed immunology panels. This new financing provides us with the resources to launch the platform in the coming months and to begin to populate it with a wide variety of proprietary assays for multiple applications."
The Maverick platform runs scalable multiplexed assays using a silicon chip that contains arrays of photonic microring sensors that can simultaneously analyze multiple proteins from a single small sample.
Assays do not require the washes, incubations, reagents or other processing steps typically associated with sample preparation. The assays are therefore simple to use and rapid -- results are available in only 15 minutes, including just two minutes of hands-on time. The Maverick platform has a large dynamic range and excellent sensitivity, with good reproducibility and no cross talk.
Dr. Gunn continued, "By using silicon-based technologies, we can provide customers with unprecedented system performance while leveraging the highly efficient production characteristic of traditional silicon chip manufacturing. During our four years of development, we and our academic collaborators generated a large number of peer-reviewed studies that provide important validation for the superiority of our detection data and the breadth of applications that are possible. We look forward to unveiling the Maverick platform at upcoming scientific meetings and to making this exciting new technology available to researchers worldwide."
Genalyte will be discussing the Maverick platform at several upcoming scientific meetings, including:
Europt(r)ode XI, Optical Chemical Sensors and Biosensors, Barcelona, Spain, April 1-4, 2012, www.europtrodexi.eu/Industrial-session.html
Immunology 2012™, the 99th Meeting of the American Association of Immunologists, Boston, MA, May 4-8, 2012, http://immunology2012.org
8th International Congress on Autoimmunity, Granada, Spain, May 9-13, 2012, www2.kenes.com/autoimmunity/pages/home.aspx
For more information about Genalyte and the Maverick platform, visit www.genalyte.com.
Since 2007, Genalyte's mission has been to develop instrument systems, hardware, software and consumables making multiplex protein and nucleic acid testing from a single sample the standard in the research, life science and clinical diagnostic markets. Genalyte's multiplexing platform incorporates the company's revolutionary Microring Sensor Technology™, a new approach to multiplexing that reduces or eliminates sample preparation, provides scalable multiplexing for both proteins and nucleic acids from a single small sample, and achieves up to eight logs of dynamic range. Genalyte is preparing to launch the Maverick™ platform, which uses this technology to run scalable multiplexed assays that do not require the washes, incubations or other processing steps associated with sample preparation. The Maverick™ platform has a large dynamic range and excellent sensitivity.
About Claremont Creek Ventures
Claremont Creek Ventures is a seed and early stage venture capital firm investing in digital healthcare, energy technology, payments/commerce, and online businesses. Claremont Creek has $300 million in capital under management in two funds. For more information, visit www.claremontcreek.com.Contacts:
Media: Martin Gleeson
BioCom Partners VP, Development & Applications
Barbara Lindheim +1 858 750-4470
+1 212 584-2276 x201 firstname.lastname@example.org
|SOURCE Genalyte, Inc.|
Copyright©2010 PR Newswire.
All rights reserved